LIGAND PHARMACEUTICALS INCORPORATED Deferred State and Local Income Tax Expense (Benefit)
LIGAND PHARMACEUTICALS INCORPORATED (LGNXZ) reported Deferred State and Local Income Tax Expense (Benefit) of $574.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit · last filed 2026-02-27
- LIGAND PHARMACEUTICALS INCORPORATED deferred state and local income tax expense (benefit) for fiscal 2025 was $574.00K, a 645.45% increase from fiscal 2024.
- LIGAND PHARMACEUTICALS INCORPORATED deferred state and local income tax expense (benefit) for fiscal 2024 was $77.00K, a 88.24% decline from fiscal 2023.
- LIGAND PHARMACEUTICALS INCORPORATED deferred state and local income tax expense (benefit) for fiscal 2023 was $655.00K, a 98.08% decline from fiscal 2022.
- LIGAND PHARMACEUTICALS INCORPORATED deferred state and local income tax expense (benefit) for fiscal 2022 was $34.14M.
| Period end | Deferred State and Local Income Tax Expense (Benefit) 12 month | Deferred State and Local Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|
| 2025-12-31 | $574.00K 10-K · filed 2026-02-27 | |
| 2024-12-31 | $77.00K 10-K · filed 2026-02-27 | |
| 2023-12-31 | $655.00K 10-K · filed 2026-02-27 | |
| 2022-12-31 | $34.14M 10-K · filed 2025-02-28 | |
| 2021-12-31 | -$1.69M 10-K · filed 2024-02-29 | -$1.26M 10-K · filed 2022-02-28 |
| 2020-12-31 | -$3.23M 10-K · filed 2023-02-28 | -$3.38M 10-K · filed 2021-02-24 |
| 2019-12-31 | $202.00K 10-K · filed 2022-02-28 | |
| 2018-12-31 | -$185.00K 10-K · filed 2021-02-24 | |
| 2017-12-31 | $228.00K 10-K · filed 2020-02-27 | |
| 2016-12-31 | -$240.00K 10-K · filed 2019-02-28 | |
| 2015-12-31 | -$24.72M 10-K · filed 2018-03-01 | -$26.22M 10-K · filed 2016-02-26 |
| 2014-12-31 | -$30.00K 10-K · filed 2017-02-28 | -$63.00K 10-K · filed 2014-12-01 |
| 2013-12-31 | -$63.00K 10-K · filed 2016-11-14 | |
| 2012-12-31 | -$297.00K 10-K · filed 2015-02-23 | |
| 2011-12-31 | -$3.13M 10-K/A · filed 2014-12-12 |